WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.084
Volume 9, Issue 13, 398-424. Review Article ISSN 2277– 7105

RECENT APPROACHES OF NANOPARTICLES IN TREATMENT OF CNS DISORDERS

Vhasale Ketan Kulbhushan[1]*, Paul Gajanan Balaji[2], Ban Satish Eknath[3] and Thorat Abhijeet Kantling[4]

[1]Dept. of Pharmaceutics, University Dept. of Pharmaceutical Sciences, Nagpur.

[2]Dept. of Pharmaceutics, AISSMS College of Pharmacy, Pune.

[3]Dept. of Pharmaceutics, NDMVP'S College of Pharmacy, Nashik.

[4]Dept. of Pharmaceutics, Modern College of Pharmacy, Nigdi, Pune.

Article Received on
27 August 2020,

Revised on 17 Sept. 2020,
Accepted on 07 October 2020

DOI: 10.20959/wjpr202013-18966

***Corresponding Author**
Vhasale Ketan Kulbhushan
Dept. of Pharmaceutics, University Dept. of Pharmaceutical Sciences, Nagpur.

Abstract

Brain disorders and their treatment is a challenging perspective nowadays. These brain disorders are defectively treated due to some hurdles regarding the poor penetration of a drug in the brain, BBB, as well as inadequate drug development maneuverings. This difficulty could be overwhelmed by recognizing nanoparticles in the treatment of brain disorders. The main benefaction of this work lies in the corresponding study of various types of not only nanoparticles but also nano formulation which could be a useful way for the treatment of brain disorders. This study shall be beneficial for the researchers to generate a new system, based on these considerations and could be helpful for further progression of new strategies.

KEYWORD: BBB, Nanoparticle, Diseases, Treatment, Properties, Current advances.

INTRODUCTION

The prefix "nano" the prefix comes from the ancient Greek word νᾶνος, which means dwarf literally through the Latin nanus, and is therefore small. In the convention of the International System of Units (SI). (Ranjit and Baquee, 2013) Nanotechnology is the science that manages matter at the size of 1 billionth of a meter (i.e., 10 − 9 m = 1 nm). (Horikoshi and Serpone, 2013) NPS is not straightforward atoms itself and hence made out of three layers. (a) The surface layer, which might be functionalized with an assortment of little molecules, metal ions, surfactant sand polymers. (b) The shell layer, which is artificially unique material from

the center in all aspects, and (c) The core, which is the focal segment of the NP and for the most part alludes to the NP itself. (Khan, Saeed and Khan, 2017) Lately, the consolidation of nanotechnology in clinical and pharmaceutical field, or otherwise called nanomedicine In light of the definition from the European Science Foundation (ESF 2004), (Cancer, 2018)Metallic nanoparticles have distinctive physical and concoction properties from mass metals (e.g., lower dissolving focuses, higher specific surface zones, specific optical properties, mechanical qualities, and specific charges), properties that may demonstrate appealing in different modern applications. (Horikoshi and Serpone, 2013) The significance of these materials acknowledged when analysts found that size can impact the physicochemical properties of a substance e.g. the optical properties. A 20nm gold (Au), platinum (Pt), silver (Ag), and palladium (Pd) NPs have trademark wine red colour, yellowish gray, black, and dull dark colors, respectively. (Horikoshi and Serpone, 2013) They have the very high surface area and allow many functional groups are attached to them which can bind to cancerous cell because they can be easily assembled in cancerous micro-environment they have proven to superb substitution for radiation and chemotherapy. Depending on the preparation methods of CNT, SCF, SAS, DSC, nanoparticles, nanospheres or nano capsules with different characteristics and release characteristics can be obtained. (Ashara and Paun, 2013)

Structure of the blood-brain barrier

Blood vessels are essential for delivering oxygen and nutrients to all tissues and organs of the body. The blood vessels that make the central nervous system (CNS) vascularized have unique characteristics, called the blood-brain barrier, which can make these blood vessels strictly regulate the movement of ions, molecules, and cells between the blood and the brain. This precise control of CNS homeostasis can achieve proper neuronal function and also protect nerve tissue from toxins and pathogens. (Banks, 2008).

Tight junction

Three cell components of the cerebral microvasculature make up the blood-brain barrier, namely endothelial cells, astrocytes, terminal feet, and pericytes (PCs). Adhesive junctions are composed of cadherin-catenin complexes and related proteins. TJ consists of three complete membrane proteins, namely claudin, occludin, and junction adhesion molecules, as well as many cytoplasmic accessory proteins, including ZO-1, ZO-2, ZO-3, cingulin, and other Cytoplasmic proteins, link membrane proteins to actin, which is the main cytoskeletal

protein that maintains the structural and functional integrity of the endothelium. (Ballabh, Braun and Nedergaard, 2004) The claudin family was identified mainly in mice and humans through database searches. They are 22 kDa phosphoproteins with four transmembrane domains. The carboxyl terminus of claudins binds to cytoplasmic proteins, including ZO-1, ZO-2, and ZO-3. (Furuse, Sasaki and Tsukita, 1999) (Greene, Campbell and Janigro, 2019) Occludin is a 65 kDa phosphorylated protein with four transmembrane domains, a long carboxy-terminal cytoplasmic domain, and a short amino-terminal cytoplasmic domain. The two extracellular loops of occludin and claudin originate from adjacent cells, forming a tightly connected paracellular barrier. The occlusive protein is directly connected to the zona pellucida occlusive protein, thereby regulating permeability through its binding to the actin cytoskeleton. JAM is a 40 kDa membrane protein within a tight junction and also binds to ZO-1. Among the three identified JAM molecules, only JAM-1 and JAM-3 were expressed in the brain endothelium, and JAM-2 was not expressed. JAM-1 localizes to actin and participates in cell adhesion (Greene, Campbell and Janigro, 2019).

Adherens junction

Adhesive junctions form adhesive contacts between cells and are composed of the membrane protein cadherin, which is connected to the actin cytoskeleton through an intermediary protein (catenin). Adhesive junctions are formed by homologous interactions between extracellular domains of cadherins on the surface of adjacent cells. The cytoplasmic domain of cadherin binds to β- or γ-catenin, which is connected to the cytoskeleton via α-catenin.(Stamatovic, Keep and Andjelkovic, 2008) (Greene, Campbell and Janigro, 2019).

Pericyte

Many vascular functions of pericytes have been identified, including regulating cerebral blood flow, maintaining the blood-brain barrier (BBB), and controlling vascular development and angiogenesis. Pericytes can also promote neuroinflammatory processes and have stem cell-like properties. Pericytes form part of a neurovascular unit (NVU), which is a collection of cells that control the interaction between neurons and the vasculature of the brain to meet the energy needs of the brain. More and more people think that peripheral cell dysfunction is the cause of vascular diseases such as stroke and neurodegenerative diseases such as Alzheimer's disease. Due to its ability to behave like stem cells, the therapeutic potential of pericytes to repair cerebral blood vessels and promote angiogenesis has recently been discovered (Fu and Wright, no date).

Astrocyte

Astrocytes are a group of cells with unique morphological and functional characteristics, which will be different in specific areas of the brain. (Siracusa, Fusco and Cuzzocrea, 2019) Astrocytes are divided into protoplast type and fibrous type. In most cases, protoplast astrocytes are mainly gray Substances and fibrous astrocytes are most common in white matter. (Montgomery, 1994) Astrocytes surpass neurons in the human brain, they play a key role in many functions of the central nervous system (CNS), including glutamic acid, ions (i.e. Ca2+, K+) and water homeostasis, antioxidant /Nitrification defense, energy storage, mitochondrial biogenesis, scar formation, tissue repair through angiogenesis and neurogenesis, and synaptic regulation. (Kim, Park and Choi, 2019).

Transport across the blood-brain barrier

Although oxygen and carbon dioxide can diffuse rapidly through the brain's endothelial cells, only the smallest lipophilic molecules with fewer than 8-10 hydrogen bonds (i.e. <400 Da) can passively diffuse through the BBB. However, because the brain needs energy in the cerebral circulation, many protein transport systems exist on the inner and outer surfaces of the brain EC to regulate molecular CNS entry and exit.

Paracellular transport

The particles move between endothelial cells through a junction complex. Tight junctions mainly mediate paracellular transport, and the movement of particles depends on the concentration of solutes. The contractile force and adhesion of the endothelial cytoskeleton control the permeability of the tightly-connected junction complex where paracellular transport occurs. (*No Title*, no date) (Fu and Wright, no date) (Weng-jiang *et al.*, 2014).

Solute carrier transporter (carrier-mediated pathway)

A form of saturation transport that mediates the exchange of particles between the circulation of the system and the substance of the brain. (Fu and Wright, no date)The blood-brain barrier (BBB) forms an interface between circulating blood and the brain and has a variety of carrier-mediated small molecule transport systems to support and protect CNS functions. For example, the blood-to-brain transport system provides nutrients such as glucose and amino acids. (Weng-jiang *et al.*, 2014) (Ohtsuki and Terasaki, 2007).

Receptor-mediated transcytosis

This pathway includes endocytosis, Intracellular vesicle transport, and exocytosis. The first of these steps may involve adsorption (depending on charge) or Receptor-mediated internalization. Positively charged molecules (such as polymers, cationic lipids, albumin, and nanoparticles) may interact with negatively charged cell membranes and be internalized by adsorption endocytosis (Pulgar, 2019). Receptor-mediated endocytosis requires a two-step process: (1) Formation of endocytic vesicles, in which receptor-ligand recognition promotes the formation of coated pores. These pits become endocytic vesicles and engulf the ligand. (2) Endosome fusion dissociates the receptor from the ligand, and its contents are released by exocytosis. Some vesicles fuse with lysosomes and lose their content due to factors such as low pH and enzyme-mediated hydrolysis, so they must never cross the blood-brain barrier into the central nervous system.(Caruso, Marino and Caffo, 2014) (Hervé, Ghinea and Scherrmann, 2008) (Lombardo *et al.*, 2020).

Efflux transport system

This mechanism actively transports particles through ATP and concentration dependence and is responsible for removing substances from the central nervous system and entering the systemic circulation, thus eliminating the accumulation of compounds that would otherwise enter through the blood-brain barrier through different pathways. The prototype efflux transporter is called glycoprotein P (gp-P). P-gp is a phosphorylated glycoprotein located on chromosome 7. It contains 27 exons. Spread over 100 kb. (Farhat *et al.*, 2013) PGP is already Brain microvascular endothelial cells and isolated brain capillary endothelial cells. (Golden and Pollack, 2003) Glycoprotein P (gp-P) is a glycosylated member of the ATP binding cassette (ABC) transporter and is expressed on the luminal membrane of endothelial cells. gp-P belongs to the multi-drug resistance receptor (MDR) class, which is characterized as a remover of ATP-dependent anticancer drugs, antibiotics, immune system inhibitors, or ion channel modulators. In brain capillaries, there is a high concentration of gp-P, which plays an important role in preventing the accumulation of toxins or drugs in the brain, and is essential to protect the viability of neurons. (‘Drug Transport and the Blood-Brain Barrier CHAPTER 8 Drug Transport and the Blood-Brain Barrier’, 2015) (Abbott *et al.*, 2010).

Classification of nanoparticle

They are classified into two types

1. Organic nanoparticle

2. Inorganic nanoparticle

1. Oraganic nanoparticle

- Liposome
- Polymeric nanoparticle
- Dendrimer
- Amphophilic cyclodextrin
- Solid lipid nanoparticle
- Micelle

2. Inorganic nanoparticle

- Gold nanoparticle
- Silver nanoparticle
- Zinc oxide nanoparticle
- Iron oxide nanoparticle
- Carbon nanotube
- Quantum Dot

1. Organic NPs

1. Liposomes

Liposomes are composed of one or two concentric Phospholipid bilayer with a structure size range between 10-100nm. (Tapeinos, Battaglini and Ciofani, 2017) Liposomes are mostly used in brain cancer therapy because they can cross BBB and also delivered a maximum number of drugs to the brain targeted site liposomes formulation which can deliver different anticancer drug such as methotrexate, 5FU, Paclitaxel, doxorubicin & erlotinib etc. Transferin is a modified liposome to deliver alpha-mangostin drug for neurodegenerative therapy. (Teleanu *et al.*, 2018).

2. Polymeric Nps: (PNPs)

The PNPs consists of the polymer matrix with particle size range between 60-200nm. (Masserini, 2013) PLGA nanoparticle is delivered Antitubercular drug to the brain. PBCA polymeric NPs is delivered anticancer drug to the brain. Starch & chitosan are natural polymer that have been used for delivery of the drug to the brain (Mc Carthy *et al.*, 2015).

3. Dendrimer

It's a synthetic micro molecule characterized by high branching points or three-dimensional globular shape with a size range between 1-100nm. (Tapeinos, Battaglini and Ciofani, 2017) PPI & PAMAM dendrimer NPs is successfully used for the delivery of the brain targeted of site. (Posadas, 2016)

4. Micelles

Micelles are amphophilic Copolymer with hydrophilic A &hydrophobic B diblock structure with size range between 5-50nm (Batrakova *et al.*, 1906). Micelles Nps have been used for the delivery of the curcumin into targeted glioma& Alzheimer's disease. (Teleanu *et al.*, 2018)

5. Solid lipids Nps

SLNp is a small particles size range between 40-200nm which cross the tight endothelial cells of the BBB & escape from the reticuloendothelial system SLNp which can improve the ability to cross BBB LDL have been used as drug delivery vehicles for a brain tumor. (Neves, Queiroz and Reis, 2016)

6. Amphophilic cyclodextrin

Amphophilic cyclodextrin is cyclic oligosaccharides synthesized by enzymatic hydrolysis potato starch (Gadade and Pekamwar, 2020). Amphophilic cyclodextrin show particles size range between 10-1000nm. Amphophilic cyclodextrin NPs are used for the delivery of the drug to the brain. (Gadade, 2020).

Inorganic NPs

1. Gold NPs (AuNps)

AuNps are one type of metallic colloidal Nps with a particles size range of less than 10nm. (Zhou *et al.*, 2018) The incorporation of AuNps with beta amyloid specific peptides which can be used in the treatment of Alzheimer's disease. The combination of the L-dopa with multi -branched nanoflower like AuNps which can be used in the treatment of Parkinson's disease. (Teleanu *et al.*, 2018).

2. Silver Nps

AgNPs are metallic colloidal Nps with particle size range between 1-100nm (Mc Carthy *et al.*, 2015). AgNPs are shows cytotoxic effect on the tumor's cells such as HeLa (adhesive

cells) & U937(suspension cells) due to this reason AgNPs have been used in the treatment of cancer cells. (Article *et al.*, 2020).

3. Carbon nanotubes(CNTs)

CNTs are pseudo one dimensional (1D) carbon allotropes of fullerenes subfamily (Hasnain *et al.*, 2019) with a diameter 0.5-20nm (Posadas, 2016). SWCNTs are linked with PL- branched PEG by esterified bond then pirarubicin loaded into its form a complex which can cross BBB & therapeutically used in the Human bladder cancer cells BIU- 87. (Sheng *et al.*, 2015).

4. Quantum dot(QD)

QDs is a semiconductor non crystal with the particles size range between 2-10nm.QDs have been released cd+2 ions which causes cytotoxicity to brain cells due to QDs are incorporated with PEG for decreased toxicity streptovidin coated WDS are conjugated with Anti EGFR antibodies that deliver in the brain tumor cells .

5. Zinc oxide Nps (ZONps)

These are made up of doping with transition metal ions. ZONps is commercially made up of NPs with particle size 20-80nm (Gadade, 2020). where recently focused on the study of the particle size However nanosized ZONps less toxic than micro- sized. ZOPs is easily penetrated BBB which can be used in the treatment of CNS. (Wang *et al.*, 2020)

6. Superparamagnetic iron oxide NPs (SPIONs)

SPIONps are prepared from maghemite(Fe2O3) or magnetite (F3O4) molecular with a size range between 10-100nm.SPIONps have been encapsulated by a different biocompatible polymer such as dextran PEG etc. For cross BBB. SPIONPs which can be conjugated with Human recombinant EGF for the delivery to the C6- glioblastoma cells. (Tekade *et al.*, 2017)

Route of administration of nanoparticles:

The administration of different types of nanoparticles can be understood by the following



Method of preparation of nanoparticles

1. Emulsion polymerization

After emulsion, anionic polymerization of alkyl cyanoacrylate monomer to polymer NP polymerization technology. In this way, the monomer is uniformly dispersed in the aqueous solution. Emulsion and stabilized by surfactant. Surfactants promote monomer emulsification to reduce the water phase by lowering the surface tension monomer-water interface. Surfactant dispersion until the critical micelle concentration (CMC) implementation. Micelles contain polar and non-polar ends. The polar head-out aggregates allow non-polar hydrocarbons to form inside, where the monomers dissolve. After the monomer is added, emulsification begins with stirring. Generally, water-soluble initiators are used in emulsions the system contains monomer droplets in the aqueous phase and dissolved monomers inside the micelles. With a water-soluble initiator, the chain growth starts at the surface of the micelle, which is hydrophilic. Once the monomer in the micelle is consumed, droplets enter from the water phase. Therefore, the polymerization reaction proceeds inward and continues

until free radicals terminate it. The emulsifier layer of the micelle stabilizes these particles until the micelles rupture and releases the particles. Nanoparticles are homogeneous disperse in the water phase and stabilize emulsion molecules originally formed micelle (Bhatia, 2016).

2. Emulsification-solvent diffusion

It consists of the formation of a conventional o/w emulsion between a water-miscible solvent containing a polymer and a drug and an aqueous solution containing a surfactant. The polymer-solvent and water are saturated with each other at room temperature to ensure the initial thermodynamics. Then use a large amount of water induces the diffusion of the solvent from the dispersed droplets to the external phase, resulting in the formation of colloidal particles. Usually, nanospheres are produced by this method, but nano-capsules can be obtained by adding a small amount of oil (such as ethylene glycol) to the organic phase. Finally, according to its boiling point, evaporation or filtration could remove the solvent. (Crucho and Barros, 2017).

3. Double Emulsion and Evaporation Method

Since degradable polymers can degrade into non-toxic components, biodegradable polymers have been widely used in drug delivery systems for encapsulating drugs and drugs. These polymers consist of ester, amide, and ether functional groups. Different polymers, such as PLA, PLGA, and PCL, are currently being intensively studied to encapsulate various active drugs, genes, and macromolecules using a double emulsification process. In this method, homogenization is performed in two steps: In the first step, the water-soluble drug is incorporated into the internal water phase (W1), and the polymer/lipophilic drug is added to the oil phase (O), And then homogenize the two phases with proper stirring to form a primary emulsion (W1/O). Then, the primary emulsion is emulsified together with an external water phase containing a suitable stabilizer to form a double emulsion (W1/O/W2). A double emulsion (particulate dispersion) is formed, and then the organic solvent (O) is evaporated from the dispersed phase, resulting in insolubility, thereby hardening the polymer encapsulating the active material. The external aqueous phase acts as a dispersion medium and can be stirred by mechanical stirring or ultrasonic treatment, depending on the nature of the drug to be encapsulated and the expected particle size. (Iqbal *et al.*, 2015).

4. Salting out method

The salting-out technique first consists in forming the oil-in-water emulsion by mechanically mixing the two phases. The oil phase is a solution of water-insoluble polymers and active

compounds in a water-miscible solvent, while the water phase is a solution or gel containing a colloidal stabilizer and a high concentration salting-out agent. The presence of the salting-out agent in the aqueous phase hinders the diffusion of the solvent. The resulting oil-in-water (o/w) emulsion is then diluted with a sufficient amount of pure water to reduce the concentration of the salting-out agent below the threshold so that the organic solvent quickly diffuses into the aqueous phase and causes interfacial turbulence and PNP form. In the next step, the solvent is removed from the PNP suspension by distillation under reduced pressure. Subsequent ultracentrifugation and repeated washing steps removed the salting-out agent, the remaining stabilizer. Alternatively, the solvent and salting-out agent can be removed by cross-flow filtration. Compared with the solvent replacement technology, due to the introduction of the high content of the polymer, a highly concentrated and stable dispersion is obtained, while the solvent replacement technology is difficult to obtain a high polymer content dispersion.(Mendoza-Munoz, Quintanar-Guerrero and Allemann, 2012).

5. Supercritical fluid technology

In the RESS method, the drug solution expands in the supercritical fluid through a nozzle, which causes a loss of the solvent capacity of the supercritical fluid and precipitates the drug as fine particles. In the PCA method, the drug solution and compressed carbon dioxide are atomized into a chamber. After removing the solvent, fine crystals precipitate out and the solution becomes supersaturated. In the supercritical antisolvent process, a supercritical fluid that is insoluble in drugs is used. The drug is dissolved in a solvent that is miscible with the supercritical fluid. After the drug solution is injected into the supercritical fluid, the supercritical fluid will extract all solvents and the drug solution will become supersaturated. The drug will then precipitate into fine crystals. The solvents used are dangerous. Also, a large number of surfactants and stabilizers are used in the cleaning process. (Mendoza-Munoz, Quintanar-Guerrero and Allemann, 2012).

Table No. 1: Various characteristics and brief applications of nanocarriers used for CNS drug delivery (Nahar *et al.*, 2006) (Wang *et al.*, 2017) (Kafa *et al.*, 2016).

Sr. No	Carrier Type	API molecule	Size (nm)	Surface Charge	Cellular Uptake	Particle material	Characteristics	Advantage
1	Carbon nanotube	Doxorubicin Acetylcholine	0.5–3 diameter and 20–1000 length	N.R.	N.R.	Graphite sheets	These crystals have remarkable strength and unique electrical properties	Enhanced solubility, penetration to cell cytoplasm and to nucleus, as carrier for gene delivery, peptide delivery
2	Dendrimer	Paclitaxel Docetaxel	<10	2.07–3.15	N.R.	Polyamidoamine Polypropyleneimine	Highly branched, nearly monodisperse polymer system produced by controlled polymerization; three main parts core, branch and surface	Higher targeting efficiency and biodistribution to the 35 brain (Gajbhiye and Jain, 2011)
3	Liposome	Oregon Green Citicoline	50-100	7.66	65–70(Yang *et al.*, 2019)	DSPC, cholesterol, DSPE	Phospholipid vesicles, biocompatible, versatile, good entrapment efficiency, offer easy	Considerable increase (10-fold) in the bioavailability of the drug in the brain parenchyma(Ramos-Cabrer *et al.*, 2011)
4	Polymeric micelles	Olanzapine	10-100	-30–20	N.R.	Block copolymers of ethylene oxide/propylene oxide	Block amphiphilic copolymer micelles, high drug entrapment, payload, biostability	Demonstrated higher drug targeting index drug targeting efficiency (520.26%)

								and direct transport percentage (80.76%)
5	Polymeric nanoparticles	Etoposide Imatinib mesylate Venlafaxine Amphotericin B Doxorubicin	10–1000	-30.8	90	PLGA and PCL PLGA Chitosan PLA-PEG-tween 80 PBCA-tween 80	Biodegradable, biocompatible, offer complete drug protection	Selective distribution with higher brain permeability Increased the extent of drug permeation to brain Better brain uptake, higher direct transport percentage drug concentration in mice brain greatly enhanced

N.R. not reported in article

Nanoparticles in the treatment of depression

Depression is a neuronal disorder. Signs consolidate low perspective, nonattendance of eagerness for step by step life, nonappearance of essentialness, low trust in direct, messing up things, and nonappearance of core interest. Often supported specific serotonin reuptake inhibitors, tricyclic antidepressants and dopamine reuptake blockers, monoamine oxidase inhibitors, and various prescriptions to treat depression. (Ekambaram, Sathali and Priyanka, 2012)There are a couple of hypotheses about debilitation, the most normally recognized is the monoamine hypothesis, which shows that a downturn is achieved by disarray in the transmission of monoaminergic, for instance, norepinephrine, serotonin, dopamine in the brain. Various reasons have also been found, for instance, the abatement of hippocampal volume and dim issue thickness, the decline of the cerebral circulatory system and brain assimilation, and the lessening of cerebrum decided neurotrophic factor levels, which are in like manner related to the pathophysiology of depression. (Lenox and Frazer, 2002)Most meds used increase the openness of monoamines in synapses by impeding the alpha-2 self and heterogeneous receptors on monoaminergic neurons to control their neuronal take-up or quell their intraneural absorption or addition their release. (Kilts, 2003) Therefore, various

non-prominent strategies, for instance, drug modification, prodrug procedures, cure carrier structures, for instance, nanoparticles, liposomes, nanoemulsions, and nosy approaches, for instance, nanoparticle-based transdermal patches, intraparenchymal, intrathecal movement can be used to grow central tactile framework centering of drugs. The inspiration driving the use of nanoparticle for the treatment of distress is they are valuable to extend the bioavailability of the meds, with help of nanoparticle the chief pass absorption can be kept up a key good way from, high carrier limit, prolonged stream time and like this such countless ominous effects can be avoided by use of nanoparticles-based drug transport. Agomelatine is an energizer. It is a melatonergic MT1/MT2 receptor agonist and has 5-HT2C receptor enemy activity. By antagonizing 5-HT2C receptors, it can construct the appearance of norepinephrine and dopamine in the frontal cortex. When Agomelatine was taken orally, expansive liver first-pass absorption and low natural half-life show a level out bioavailability of 5%. This can be overpowered by the arranging of a nanoparticle-based transdermal fix of drug agomelatine. (Shinde, Salve and Rathod, 2019) Hibiscus Rosa Chinese. It is an ornamental plant normally called China rose. It is used as a male sexual enhancer and embryo expulsion drug to treat depression, male productivity, and improve lung prosperity. The energizer activity of the plant is appeared by normalizing the neurotransmitters serotonin, dopamine, and norepinephrine in the cerebrum. It is furthermore offered an explanation to show strong MAO-An inhibitory activity. The difference in Hibiscus Rosa Sinensis to SLNs can improve its oral association bioavailability and henceforth the ampleness of the move in remunerating depression. (Vijayanand *et al.*, 2018)Through the uncommon olfactory zone arranged at the top of the nasal cavity, the therapeutic part can be brought into the psyche, whose neuroepithelial cells are simply a bit of the CNS direct introduced to the outside condition. NP is brought to the central tangible framework through the olfactory nerve epithelial cells through the trigeminal tactile framework and the olfactory nerve pathway. Hereafter, the improvement of intranasal nanoparticles for the treatment of despairing might be helpful. (Haque *et al.*, 2014) Iron has various limits in nerve cells, which can be used for oxidoreductase, the maintenance, and transmission of neural connections, the turn of events, and the processing of cerebrum myelin. What's more, iron is key for the association of brain neural connections, (for instance, serotonin, dopamine, norepinephrine, and gamma-aminobutyric destructive). Evidence shows that iron supplementation is 25% Improve the weight and hopelessness of mothers with iron need. Thusly iron oxide nanoparticle can be useful in the treatment of depression(Saeidienik *et al.*, 2018)

Nanoparticles in the treatment of alzheimer disease

Alzheimer's disease (AD) is a devastating neurodegenerative disease characterized by progressive and irreversible caused the extensive death of neurons in the brain area, uniquely the neocortex (Kocahan and Do, 2017), particularly in the temporal and parietal lobes. (Karthivashan *et al.*, 2018) The generation of neurons will affect cognition (learning, abstraction, judgment, etc.) and memory of behaviours, such as aggression, depression, hallucinations, delusions, anger, and excitement. (Roney *et al.*, 2005) This disease is the most common form of dementia and the fourth leading cause of death among people over 65 years of age. Currently, an estimated 24 million people worldwide suffer from dementia. By 2020, the affected population will double, reaching 81 million by 2040. (Roney *et al.*, 2005) A large number of abnormal iron accumulation sites are found in the pathological changes of AD, which can serve as redox-active canters-senile plaques (SP) and neurofibrillary tangles (NFT). (Harilal *et al.*, 2019) According to reports, three mutated genes can cause AD, including the gene encoding amyloid precursor protein (APP) on chromosome 21, the gene encoding presenilin 1 (PS1) on chromosome 14, and the gene encoding presenilin2 (PS2) is located on chromosome 1. These mutations can cause the amyloid-beta protein (Aβ) to form senile plaques outside the cell, while the microtubule-associated protein tau (tau) is hyperphosphorylated to form neurofibrillary tangles. Many clinical data indicate that AD patients show severe damage to the cholinergic neurotransmitter system, which may be due to acetylcholinesterase (AChE) activity inhibiting acetylcholine.

Table no. 2: Information about Polymeric nano delivery with drug delivered and its significance.

Study no.	Polymeric nano - delivery	Targeted against	Drug delivered	significance	Ref
1	Nano-capsule	Neuro inflammation against beta – amyloid in Alzheimer disease	Curcumin Meloxicam Indomethacin	Decrease beta – amyloid plaques, delayed degradation of neuron, antioxidant, anti-inflammatory, decrease microglia formation and neuroprotective.	(Greene, Campbell and Janigro, 2019) , (Fu and Wright, no date), (Siracusa, Fusco and Cuzzocrea, 2019)
2	Nanogel	Brain deliver against beta – amyloid in Alzheimer disease	Chaperon donepezil	Inhibit the formation of beta-amyloid protein. inhibit the	(Montgomery, 1994), (Kim, Park and Choi,

				acetylcholinesterase inhibitor.	2019),(Farhat *et al.*, 2013)
3	Nano micelles	Beta-amyloid protein plaque formation	Ubisol-Q10	Neuroprotective.	(*No Title*, no date)
4	Nanoliposome	Beta-amyloid protein in Alzheimer disease	Baicalein	Inhibiting aggregation of disease-specific amyloid Protein.	(Weng-jiang *et al.*, 2014)
5	Nano emulsion	Beta-amyloid in Alzheimer disease	Naringenin	Reducing oxidative stress, Anti-inflammatory and Inhibiting beta-amyloid protein.	(Ohtsuki and Terasaki, 2007)

NPs in the treatment of Parkinson's disease (PD)

PD is the second most common neurodegenerative disorder due to loss of neurons in substantia nigra pars compacta & also nuclei within the basal ganglia. (Kaushik *et al.*, 2018) Dysfunction of the body due to degeneration of the basal ganglia which involves motor and non-motor system like bradykinesia, rigidity, postural, instability, akinesia, &resting tremor. (Leyva-Gómez *et al.*, 2015) Several medical & surgical treatments are currently available but show adverse side effects due to the long term used. Hence Novel NPs drug delivery system is effectively used in the treatment of the PD. (Jayaraj, Chandramohan and Namasivayam, 2013)

Current advances

In the event of intrathecal medicate organization, the medications have restricted capacity to enter the extracellular space of the cerebrum from the CSF. The convection upgraded dissemination procedure is utilized in transcranial mind sedate conveyance ways to deal with sidestep the BBB for the strong conveyance of liquid into the cerebrum and to expand the powerful penetration of medication into the area. Then again, the receptor-intervened endocytosis and exocytosis encourage the section of the restorative mixes over the BBB of cerebrum. Another customary way to deal with taking care of the issue of medication) conveyance into the mind is BBB disturbance. A promising medication conveyance strategy that can sidestep the BBB is the utilization of an intranasal tranquilize conveyance course. (Manuscript, 2013)

BBB and sick cell double focused on conveyance

Even though cerebrum focusing on conveyance frameworks could upgrade the dissemination of medications in mind, the appropriation of NPs in the cerebrum after entering through BBB or in the wake of bypassing the BBB is a major concern. If the NPS unselectively circulate in the entire mind, the improvement of treatment result brought about by raised medication fixation may go with far and away more terrible reaction to CNS. Moreover, as one of the most significant organs, the cerebrum is increasingly touchy to poisons.

1. Viable infiltration of the BBB or bypassing BBB,
2. Specifically focusing on infected cells while limiting the appropriation into typical synapses. To accomplish these two objectives, double cerebrum focusing on sedate conveyance frameworks were created. Regularly, the "double cerebrum focusing on" signifies there are ligands for the mind focusing on and ligands for sick cells in a single medication conveyance framework. On the off chance that a ligand could target both cerebrum and sick synapses, the ligand-changed medication conveyance framework likewise can be considered as a double mind focusing on a sedate conveyance framework. (Gao, 2016a)

1. Two ligand adjustment for two targets

To exhibit the chance, we developed a sort of angiopep-2 and EGFP EGF1 double altered NPs for explicitly focusing on neuroglial cells in typical cerebrum because the low-thickness lipoprotein receptor-related protein is overexpressed on the BBB, and therefore could tie with EGFP-EGF1, which is overexpressed on neuroglial cells while insignificantly communicated on endothelial cells. 3 cells (a for the most part utilized cell line to speak to BCECs) as opposed to neuroglial cells, while the EGFPEGF1 adjustment explicitly improved cell take-up by neuroglial cells instead of bEnd. Thusly, the double adjustment could improve cell take-up by the two sorts of cells. (Zhao and Townsend, 2009) In vivo, the collection of As TNPs in mind was overlaying higher than that of unmodified NPs. More critically, to assess the glioma-particular circulation in the cerebrum, the force proportion of glioma to mind was assessed. Conversely, the T/N proportion of As TNPs was as high as, recommending that double adjustment could not just improve the gathering in mind tumor yet besides the selectivity in the cerebrum. Roughly 96% of the absolute Aβ is Aβ1–42, the most harmful isoform that has a high inclination toward total. (Allaman *et al.*, 2010) In this way, Aβ1–42 is a promising objective for the treatment of AD. QSH peptide (QSHYRHISPAQV) was chosen to utilize a perfect representation phage show against Aβ1–42. Both in mice and people, QSH

demonstrated high restricting liking with Aβ1–42Therefore, Zhang et al. (Gao, 2016b) Thus, the spatial learning and memory of the AD model mice in the H102-stacked TQNPs gathering, as exhibited by the Morris water labyrinth test, were essentially improved contrasted and the AD control bunch just as the other treatment bunch including the H102-stacked TNPs gathering. The nerve cell harm brought about by A gathering in the hippocampus was essentially lessened by the treatment of H102 stacked TQNPs, which was like a solid cerebrum. These outcomes showed that the double mind focusing on the conveyance framework could significantly improve the treatment result of AD, which is better than the customary cerebrum focusing on tranquilizing conveyance framework and consequently speaks to a promising heading in this field. (Asati, 2018) (Chemotherapy, 2018) Tfn and tamoxifen (to restrain MDR protein), WGA and Tf, Dmanno-pyranoside and Tf, cationic cow-like serum egg whites and mannose, angiopep-2 and RGD, angiopep-2 and tLyP-1 (for a neuropilin-1 receptor), des-octenyl ghrelin (for Tf receptor) and folate (for folate receptor), Tf and folate, mannose nutrient E subordinate (for glucose transporters) and dequaliniumlipid subsidiary (for adsorptive intervened transportation), OX26 and chlorotoxin, (Huang *et al.*, 2016) (Yue *et al.*, 2014) lactoferrin and folate,(Wang *et al.*, 2019) c(RGDyK) and folate, phosphatidic corrosive (for Aβ authoritative) and an Apo determined peptide, Tf and nutrient E(. In any case, these investigations concentrated principally on the improved cell selectivity and disguise by multivalent impact as opposed to the capacity to overcome distinctive hindrance successively. (Agrawal *et al.*, 2016).

2. Fusion proteins and peptides

Combination proteins and peptides could be utilized for double-focusing on because they can consolidate the dynamic spaces of two ligands into one ligand. Partridge's gathering created numerous combination proteins to deliver remedial monoclonal antibodies with BBB entering capacity. Nonetheless, these proteins were for the most part utilized as medications legitimately instead of focusing on ligands in the announced examinations. (Li and Qian, 2002).

3. One ligand for one objective on two locales

Notwithstanding combination proteins or peptides, a few ligands can legitimately target two destinations because their receptors or transporters are overexpressed on both BBB and ailing synapses, for example, LRP and Tf receptor. (Demeule *et al.*, 2008) Angiopep-2 (TFFYGGSRGKRNNFKTEEY, sub-atomic weight 2.4 kDa) has a place with a family called

Angio pep, which was gotten from the Kunitz space of aprotinin. (Wiley *et al.*, 2013) Angiopep-2 shows high restricting partiality with LRP, and subsequently, it could go about as a double-focusing on the ligand to convey NPs that enter BBB and target mind. In mind tumour-bearing mice angiopep-2 change could not just build the appropriation in the cerebrum yet additionally the dispersion i cerebrum. As of late, a few investigations were utilizing angiopep-2 as a double-focusing on the ligand to effectively convey inorganic NPs, for example, gold NPs and up transformation nanoprobes, to cerebrum for analysis or treatment. Notwithstanding receptors, there likewise are a few transporters overexpressed on both the BBB and in mind cells. In vitro, the cerebrum collection of 2-deoxy-D-glucose-changed NPS was impressively higher than that of unmodified NPs, bringing about extraordinarily longer middle endurance time of mind tumor-bearing mice. Enormous amino corrosive transporter 1 additionally is overexpressed on both BBB and glioma cells, in this manner both glutamate and phenylalanine could adequately improve the conveyance proficiency of NPs to glioma through double-focusing on technique. (Pandey *et al.*, 2015)

4. Combining intranasal organization and sick cell focusing on

Histological examinations demonstrated that the lactoferrin receptor was overexpressed on the apical surface of respiratory epithelial cells, cerebrum endothelial cells, and neurons, and the overexpression of lactoferrin receptor in the CNS was related with age-related neurodegenerative infections. The AUC of lactoferrin-changed NPs in the hippocampus was 2. Thusly, the memory of AD mice rewarded with NAP-stacked lactoferrin-adjusted NPS was altogether better than that of mice rewarded with unmodified NPs. The neuron thickness in the hippocampus was additionally significantly higher than that of mice rewarded with unmodified NPs. (Aliakbari *et al.*, 2018).

5. Combining FUS and unhealthy cell focusing on

As a technique to open the BBB, FUS likewise could be joined with mind cell-focusing on NPS. Vascular endothelial development factor A can tie with and actuate cerebrum endothelial cells overexpressing VEGF receptor tyrosine kinase type R2 to direct mind angiogenesis. Although FUS blend with 1,3-bis - 1-nitrosourea stacked microbubbles could successfully convey BCNU to the cerebrum, the change of microbubbles with VEGF-A ligand joined with FUS further improved the mind focus from 24. Therefore, the cerebrum development speed of mix treatment (from day 6 to day 34 expanded 5. 02 occasions) was significantly lower than that of FUS joined with BCNU stacked unmodified microbubbles

(from day 6 to day 34 expanded 18. 54 occasions), and the middle endurance time likewise expands. (Pardridge, 2015).

Significant worries in building cerebrum focused on conveyance frameworks

1. Medication discharge during transport of the medication conveyance frameworks

Although the medication conveyance frameworks, and particularly the double-focusing on sedate conveyance frameworks, upgraded the focusing on viability for unhealthy synapses and improved the helpful result of medication treatment, the medication stacked conveyance frameworks likewise circulated to ordinary tissues, which may cause tranquilize started antagonistic impacts. Furthermore, tranquilize discharge in the blood course would lessen the medication fixation in the objective site. Hence, an alluring medication conveyance framework should keep most medication bound during conveyance methodology and in ordinary tissues, and rapidly discharge drugs when they show up at the objective site. To address this objective, our gathering developed a pH-delicate double-focusing on the conveyance framework, and the model medication, doxorubicin was tied down utilizing a hydrazine bond. (Lutchmansingh *et al.*, 2018) created NPs with a crosslinker to cover the medication containing centre, which adequately kept the medication from discharge during the conveyance methodology. At the point when the framework arrived at the focused on the, the linker was protected by the exceptionally thought glutathione (GSH) in cells. (Shilo *et al.*, 2015).

2. The homogeneity of mind focusing on tranquilize conveyance frameworks

In the medication conveyance frameworks, numerous variables can influence the focusing on productivity, for example, molecule size, surface properties, ligand properties, and ligand thickness. For instance, Pang et al. discovered the improved number of OX26 conjugated per polymer a few was 34 because more OX26 prompted faster leeway from blood and less OX26 prompted poor focusing on capacity. The absence of homogeneity may reduce the focus on the productivity of these frameworks. Taking molecule size as another model: The molecule size of NPS impressively influences the in vivo conduct and conveyance of NPs. For instance, the cut-off pore size of the U87 mind model is 7 100 nm20, which means tranquilize conveyance frameworks with a size higher than 100 nm would experience issues getting to U87 cerebrum.(‘Instructions for use’, no date) Moreover, the molecule size can influence the end and entrance in ailments tissues, for example, to address this issue, a few

sorts of size alterable NPs were created, which demonstrated both better maintenance and entrance.(Hirsjärvi *et al.*, 2013).

CONCLUSION

The blood vessels that make the central nervous system vascularized have unique characteristics, called the blood-brain barrier, which can make these blood vessels strictly regulate the movement of ions, molecules and cells between the blood and the brain. Three cell components of the cerebral microvasculature make up the blood-brain barrier, namely endothelial cells, astrocytes, terminal feet, and pericyte. These days mainstream researchers are keen on giving answers for this issue, and it isn't astounding that a large portion of the cerebrum patients could profit by the improved medication conveyance draws near. Hardly any settled methodologies are intra-blood vessel medicate conveyance, intrathecal and intraventricular medication organization, intratumorally conveyance, receptor-intervened transport, interruption of BBB, hindrance of medication efflux by BBB, and the utilization of intranasal tranquilize conveyance course. This information may be helpful for the further study of nanoparticle in the treatment of CNS disorders.

REFERENCES

1. Abbott, N. J. *et al.* 'Neurobiology of Disease Structure and function of the blood – brain barrier', *Neurobiology of Disease*. Elsevier Inc., 2010; 37(1): 13–25. doi: 10.1016/j.nbd.2009.07.030.
2. Agrawal, P. *et al.* 'Transferrin receptor-targeted vitamin E TPGS micelles for brain cancer therapy : preparation, characterization and brain distribution in rats Transferrin receptor-targeted vitamin E TPGS micelles for brain cancer therapy: preparation, characterization, 2016; 7544. doi: 10.3109/10717544.2015.1094681.
3. Aliakbari, F. *et al.* 'Formulation and anti-neurotoxic activity of baicalein-incorporating neutral nanoliposome', *Colloids and Surfaces B: Biointerfaces*. Elsevier B.V., 2018; 161: 578–587. doi: 10.1016/j.colsurfb.2017.11.023.
4. Allaman, I. *et al.* 'Amyloid- $^{N}_{L}$ Aggregates Cause Alterations of Astrocytic Metabolic Phenotype : Impact on Neuronal Viability, 2010; 30(9): 3326–3338. doi: 10.1523/JNEUROSCI.5098-09.2010.
5. Article, R. *et al.* 'REVIEW ON GREEN SYNTHESIS OF SILVER NANOPARTICLES, 2020; 9(6). doi: 10.20959/wjpr20206-17719.
6. Asati, S. 'RGD Peptide as a Targeting Moiety for Theranostic Purpose : An Update Study

RGD Peptide as a Targeting Moiety for Theranostic Purpose : An Update Study', *International Journal of Peptide Research and Therapeutics*. Springer Netherlands, 2018; 0(0), p. 0. doi: 10.1007/s10989-018-9728-3.

7. Ashara, K. and Paun, J. 'NANOPARTICULATE DRUG DELIVERY SYSTEM : A NOVEL APPROACH NANOPARTICULATE DRUG DELIVERY SYSTEM : A NOVEL APPROACH', 2013. doi: 10.22270/ijdra.v1i2.109.
8. Ballabh, P., Braun, A. and Nedergaard, M. 'The blood – brain barrier : an overview Structure, regulation, and clinical implications', 2004; 16: 1–13. doi: 10.1016/j.nbd.2003.12.016.
9. Banks, W. A. 'Regulatory Peptides The blood-brain barrier : Connecting the gut and the brain, 2008; 149: 11–14. doi: 10.1016/j.regpep.2007.08.027.
10. Batrakova, E. V *et al.* 'Polymer Micelles as Drug Carriers, 1906.
11. Bhatia, S. *Natural polymer drug delivery systems: Nanoparticles, plants, and algae, Natural Polymer Drug Delivery Systems: Nanoparticles, Plants, and Algae*, 2016. doi: 10.1007/978-3-319-41129-3.
12. Cancer, L. 'Nanoparticles as Carriers of Phytochemicals : Recent Applications Against Original Article Nanoparticles as Carriers of Phytochemicals : Recent Applications Against Lung Cancer, 2018.
13. Caruso, G., Marino, D. and Caffo, M. 'Nanoparticles and CNS Delivery of Therapeutic Agents in the Treatment of Primary Brain Tumors, 2014; 105–112.
14. Chemotherapy, B. C. 'HHS Public Access, 2018; 100–118. doi: 10.1016/j.jconrel.2017.09.026.Preclinical.
15. Crucho, C. I. C. and Barros, M. T. 'Polymeric nanoparticles: A study on the preparation variables and characterization methods', *Materials Science and Engineering C*. Elsevier B.V., 2017; 80: 771–784. doi: 10.1016/j.msec.2017.06.004.
16. Demeule, M. *et al.* 'Identification and Design of Peptides as a New Drug Delivery System for the Brain, 2008; 324(3): 1064–1072. doi: 10.1124/jpet.107.131318.Parkinson.
17. 'Drug Transport and the Blood-Brain Barrier CHAPTER 8 Drug Transport and the Blood-Brain Barrier', 2015. doi: 10.2174/978160805120511101010144.
18. Ekambaram, P., Sathali, A. H. and Priyanka, K. 'Solid lipid nanoparticles- A review', *International Journal of Applied Pharmaceutics*, 2012; 2(2): 80–102.
19. Farhat, K. *et al.* 'P-glycoprotein in blood brain barrier', 2013.
20. Fu, B. M. and Wright, N. T. (no date) *Molecular , Cellular , and Tissue Engineering of the Vascular System*.

21. Furuse, M., Sasaki, H. and Tsukita, S. 'Between Tight Junction Strands', 1999; 147(4): 891–903.
22. Gadade, D. 'ce pt ed us cr t', 2020; 2019. doi: 10.34172/apb.2020.022.
23. Gadade, D. D. and Pekamwar, S. S. 'Cyclodextrin Based Nanoparticles for Drug Delivery and Theranostics', *Tabriz University of Medical Sciences*, 2020; 10(2): 166–183. doi: 10.34172/apb.2020.022.
24. Gajbhiye, V. and Jain, N. K. 'The treatment of Glioblastoma Xenografts by surfactant conjugated dendritic nanoconjugates.', *Biomaterials*. Netherlands, 2011; 32(26): 6213–6225. doi: 10.1016/j.biomaterials.2011.04.057.
25. Gao, H. 'Progress and perspectives on targeting nanoparticles for brain drug delivery', *Acta Pharmaceutica Sinica B*. Elsevier, 2016; 6(4): 268–286. doi: 10.1016/j.apsb.2016.05.013.
26. Gao, H. 'Progress and Perspectives on Targeting Nanoparticles for Brain Drug Delivery Progress and perspectives on targeting nanoparticles for brain drug delivery', *Acta Pharmaceutica Sinica B*. Elsevier, (June), 2016; 1–19. doi: 10.1016/j.apsb.2016.05.013.
27. Golden, P. L. and Pollack, G. M. 'Blood – Brain Barrier Efflux Transport', 2003; 92(9): 1739–1753.
28. Greene, C., Campbell, M. and Janigro, D. *Fundamentals of Brain – Barrier, Nervous System Drug Delivery*. Elsevier Inc, 2019; doi: 10.1016/B978-0-12-813997-4.00001-3.
29. Haque, S. *et al.* 'Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression', *Journal of Psychiatric Research*. Elsevier Ltd, 2014; 48(1): 1–12. doi: 10.1016/j.jpsychires.2013.10.011.
30. Harilal, S. *et al.* 'Advancements in nanotherapeutics for Alzheimer ' s disease : current perspectives', 2019; doi: 10.1111/jphp.13132.
31. Hasnain, M. S. *et al. Stimuli-responsive carbon nanotubes for targeted drug delivery, Stimuli Responsive Polymeric Nanocarriers for Drug Delivery Applications*. Elsevier Ltd, 2019. doi: 10.1016/B978-0-08-101995-5.00015-5.
32. Hervé, F., Ghinea, N. and Scherrmann, J. 'CNS Delivery Via Adsorptive Transcytosis', 2008; 10(3). doi: 10.1208/s12248-008-9055-2.
33. Hirsjärvi, S. *et al.* 'Effect of particle size on the biodistribution of lipid nanocapsules : Comparison between nuclear and fluorescence imaging and counting . To cite this version : HAL, 2013. Id : inserm-00855672'.
34. Horikoshi, S. and Serpone, N. 'Introduction to Nanoparticles', 2013; 1–24.
35. Huang, D. *et al.* 'Multi-targeting NGR-modified liposomes recognizing glioma tumor

cells and vasculogenic mimicry for improving anti-glioma therapy', 2016; 7(28).

36. 'Instructions for use' (no date).
37. Iqbal, M. *et al.* 'Double emulsion solvent evaporation techniques used for drug encapsulation', *International journal of pharmaceutics*, 2015. 496. doi: 10.1016/j.ijpharm.2015.10.057.
38. Jayaraj, R. L., Chandramohan, V. and Namasivayam, E. 'Nanomedicines for parkinson disease: Current status and future perspective', *International Journal of Pharma and Bio Sciences*, 2013; 4(1): 692–704.
39. Kafa, H. *et al.* 'PT SC', *Journal of Controlled Release*. Elsevier B.V, 2016. doi: 10.1016/j.jconrel.2016.01.031.
40. Karthivashan, G. *et al.* 'Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer ' s disease', *Drug Delivery*. Informa Healthcare USA, Inc, 2018; 307–320. doi: 10.1080/10717544.2018.1428243.
41. Kaushik, A. C. *et al.* 'Nano-particle mediated inhibition of Parkinson's disease using computational biology approach', *Scientific Reports*, 2018; 8(1): 1–8. doi: 10.1038/s41598-018-27580-1.
42. Khan, Ibrahim, Saeed, K. and Khan, Idrees 'Nanoparticles : Properties , Applications and Toxicities Nanoparticles: Properties, applications and toxicities', *Arabian Journal of Chemistry*. The Authors, (May), 2017. doi: 10.1016/j.arabjc.2017.05.011.
43. Kilts, C. D. 'Potential new drug delivery systems for antidepressants: an overview.', *The Journal of clinical psychiatry*. United States, 2003; 64(1): 31–33.
44. Kim, Y., Park, J. and Choi, Y. K. 'The Role of Astrocytes in the Central Nervous System Focused on BK Channel and Heme Oxygenase Metabolites : A Review', 2019; 7–13.
45. Kocahan, S. and Do, Z. 'Mechanisms of Alzheimer's Disease Pathogenesis and Prevention : The Brain , Neural Pathology , N-methyl-D-aspartate Receptors , Tau Protein and Other Risk Factors', 2017; 15(1): 1–8.
46. Lenox, R. H. and Frazer, A. 'Mechanism of action of antidepressants and mood stablizers', *Neuropsychopharmacology: The Fifth Generation of Progress*, 2002; 1139–1163.
47. Leyva-Gómez, G. *et al.* 'Nanoparticle technology for treatment of Parkinson's disease: the role of surface phenomena in reaching the brain', *Drug Discovery Today*. Elsevier Ltd, 2015; 20(7): 824–837. doi: 10.1016/j.drudis.2015.02.009.
48. Li, H. and Qian, Z. M. 'Transferrin / Transferrin Receptor- Mediated Drug Delivery', 2002; 22(3): 225–250. doi: 10.1002/med.10008.

49. Lombardo, S. M. *et al.* 'Key for crossing the BBB with nanoparticles : the rational design', 2020; (866): 866–883. doi: 10.3762/bjnano.11.72.
50. Lutchmansingh, F. K. *et al.* 'Glutathione metabolism in type 2 diabetes and its relationship with microvascular complications and glycemia', 2018; 1–12.
51. Manuscript, A. 'NIH Public Access', 2013; 32(21): 4943–4950. doi: 10.1016/j.biomaterials.2011.03.031.Targeting.
52. Masserini, M. (2013) 'Nanoparticles for Brain Drug Delivery', *ISRN Biochemistry*, 2013; 1–18. doi: 10.1155/2013/238428.
53. Mc Carthy, D. J. *et al.* 'Nanoparticles and the blood-brain barrier: Advancing from in-vitro models towards therapeutic significance', *Pharmaceutical Research*, 2015; 32(4): 1161–1185. doi: 10.1007/s11095-014-1545-6.
54. Mendoza-Munoz, N., Quintanar-Guerrero, D. and Allemann, E. 'The Impact of the Salting-Out Technique on the Preparation of Colloidal Particulate Systems for Pharmaceutical Applications', *Recent Patents on Drug Delivery & Formulation*, 2012; doi: 10.2174/187221112802652688.
55. Montgomery, D. L. 'Astrocytes : Form , Functions , and Roles in Disease', 1994; 167: 145–167.
56. Nahar, M. *et al.* 'Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives.', *Critical reviews in therapeutic drug carrier systems*. United States, 2006; 23(4): 259–318. doi: 10.1615/critrevtherdrugcarriersyst.v23.i4.10.
57. Neves, A. R., Queiroz, J. F. and Reis, S. 'Brain ‐ targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E', *Journal of Nanobiotechnology*. BioMed Central, 2016; 1–11. doi: 10.1186/s12951-016-0177-x. *No Title* (no date).
58. Ohtsuki, S. and Terasaki, T. 'Expert Review Contribution of Carrier-Mediated Transport Systems to the Blood – Brain Barrier as a Supporting and Protecting Interface for the Brain ; Importance for CNS Drug Discovery and Development', 2007; 24(9). doi: 10.1007/s11095-007-9374-5.
59. Pandey, V. *et al.* 'Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma', 2015; 7544. doi: 10.3109/10717544.2013.877100.
60. Pardridge, W. M. 'Brain Drug Development and Brain Drug Targeting Expert Review

Drug Targeting to the Brain', 2015; 2007. doi: 10.1007/s11095-007-9387-0.

61. Posadas, I. 'Nanoparticles for brain-specific drug and genetic material delivery , imaging and diagnosis', 2016; 11: 833–849.
62. Pulgar, V. M. 'Transcytosis to Cross the Blood Brain Barrier , New Advancements and Challenges', 2019; 12: 1–9. doi: 10.3389/fnins.2018.01019.
63. Ramos-Cabrer, P. *et al.* 'Serial MRI study of the enhanced therapeutic effects of liposome-encapsulated citicoline in cerebral ischemia.', *International journal of pharmaceutics*. Netherlands, 2011; 405(1–2): 228–233. doi: 10.1016/j.ijpharm.2010.12.014.
64. Ranjit, K. and Baquee, A. A. 'International research journal of pharmacy', 2013; 4(4), 47–57. doi: 10.7897/2230-8407.04408.
65. Roney, C. *et al.* 'Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease', *Journal of Controlled Release*, 2005; 108(2–3): 193–214. doi: 10.1016/j.jconrel.2005.07.024.
66. Saeidienik, F. *et al.* 'Research Paper: The Effects of Iron Oxide Nanoparticles Administration on Depression Symptoms Induced by LPS in Male Wistar Rats', 2018; 9(3): 209–216.
67. Sheng, B. *et al.* 'Carbon nanotubes for delivery of small molecule drugs ☆', *Advanced Drug Delivery Reviews*. Elsevier B.V., 2015; 65(15): 1964–2015. doi: 10.1016/j.addr.2013.08.005.
68. Shilo, M. *et al.* 'The effect of nanoparticle size on the probability to cross the blood - brain barrier : an in-vitro endothelial cell model', 2015; 1–7. doi: 10.1186/s12951-015-0075-7.
69. Shinde, M., Salve, P. and Rathod, S. 'Development and Evaluation of Nanoparticles Based Transdermal Patch of Agomelatine for the Treatment of Depression', 2019; 9: 126–144.
70. Siracusa, R., Fusco, R. and Cuzzocrea, S. 'Astrocytes : role and functions in brain pathologies i v o r l a n o v l', 2019. doi: 10.3389/fphar.2019.01114.
71. Stamatovic, S. M., Keep, R. F. and Andjelkovic, A. V 'Brain Endothelial Cell-Cell Junctions : How to " Open " the Blood Brain Barrier', 2008; 179–192.
72. Tapeinos, C., Battaglini, M. and Ciofani, G. 'Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases', *Journal of Controlled Release*. Elsevier B.V, 2017; 264: 306–332. doi:

10.1016/j.jconrel.2017.08.033.

73. Tekade, R. K. *et al. Nanotechnology for the Development of Nanomedicine, Nanotechnology-Based Approaches for Targeting and delivery of Drugs and Genes*. Elsevier Inc, 2017; doi: 10.1016/B978-0-12-809717-5.00001-4.
74. Teleanu, D. M. *et al.* 'Blood-brain delivery methods using nanotechnology', *Pharmaceutics*, 2018; 10(4): 1–16. doi: 10.3390/pharmaceutics10040269.
75. Vijayanand, P. *et al.* 'Development and Characterization of Solid Lipid Nanoparticles Containing Herbal Extract : In Vivo Antidepressant Activity', 2018.
76. Wang, J. *et al.* 'Receptor-targeted quantum dots : fluorescent probes for brain tumor diagnosis', 2020; 12(2007): 1–7. doi: 10.1117/1.2764463.
77. Wang, S. *et al.* 'Augmented glioma-targeted theranostics using multifunctional polymer-coated carbon nanodots.', *Biomaterials*. Netherlands, 2017; 141: 29–39. doi: 10.1016/j.biomaterials.2017.05.040.
78. Wang, X. *et al.* 'Liposomes for Targeted Therapy of Glioma', 2019.
79. Weng-jiang, X. *et al.* 'The blood-brain barrier : Structure, function and therapeutic approaches to cross it', 2014;7688(5): 152–167. doi: 10.3109/09687688.2014.937468.
80. Wiley, D. T. *et al.* 'Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor', 2013; 110(21): 8662–8667. doi: 10.1073/pnas.1307152110.
81. Yang, J.-T. *et al.* 'Protection against Neurodegeneration in the Hippocampus Using Sialic Acid- and 5-HT-Moduline-Conjugated Lipopolymer Nanoparticles', *ACS Biomaterials Science & Engineering*. American Chemical Society, 2019; 5(3): 1311–1320. doi: 10.1021/acsbiomaterials.8b01334.
82. Yue, P. *et al.* 'OX26 / CTX-conjugated PEGylated liposome as a dual-targeting gene delivery system for brain glioma', 2014; 1–13.
83. Zhao, W. and Townsend, M. 'Biochimica et Biophysica Acta Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer ' s disease', *BBA - Molecular Basis of Disease*. Elsevier B.V., 2009; 1792(5): 482–496. doi: 10.1016/j.bbadis.2008.10.014.
84. Zhou, Y. *et al.* 'Crossing the blood-brain barrier with nanoparticles', *Journal of Controlled Release*. Elsevier B.V, 2018; 270: 290–303. doi: 10.1016/j.jconrel.2017.12.015.